Free Trial

Taro Pharmaceutical Industries (TARO) Stock Price, News & Analysis

0.00 (0.00%)
(As of 06/24/2024)
Today's Range
50-Day Range
52-Week Range
Average Volume
45,199 shs
Market Capitalization
$1.62 billion
P/E Ratio
Dividend Yield
Price Target
TARO stock logo

About Taro Pharmaceutical Industries Stock (NYSE:TARO)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Stock Price History

TARO Stock News Headlines

Sun Pharma Completes Taro Merger
Central Bank Ditches U.S. Dollar
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Taro: Fiscal Q4 Earnings Snapshot
Central Bank Ditches U.S. Dollar
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Taro to Release Full Year Results on May 20, 2024
See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$53.87 million
Pretax Margin


Sales & Book Value

Annual Sales
$629.18 million
Cash Flow
$2.38 per share
Book Value
$47.70 per share


Free Float
Market Cap
$1.62 billion
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Uday V. Baldota (Age 54)
    CEO & Director
  • Mr. William J. Coote (Age 69)
    VP, CFO & Chief Accounting Officer
  • Mr. Itamar Karsenti (Age 52)
    VP & Head of Operations
  • Mr. Avi Avramoff (Age 59)
    VP and Head of R&D
  • Mr. Itzik Baruch (Age 61)
    Vice President of Technical Services
  • Dr. Roman Kaplan (Age 77)
    Vice President of Scientific and Technical Compliance Manager
  • Mr. Erik Zwicker J.D. (Age 44)
    VP, General Counsel & Secretary
  • Mr. Ara Aprahamian (Age 56)
    Vice President of Sales & Marketing
    Comp: $616.14k
  • Ms. Michele Visosky (Age 58)
    VP & Head of Human Resource
  • Mr. Jayesh Shah (Age 68)
    Head of Procurement

TARO Stock Analysis - Frequently Asked Questions

How have TARO shares performed this year?

Taro Pharmaceutical Industries' stock was trading at $41.78 on January 1st, 2024. Since then, TARO stock has increased by 2.8% and is now trading at $42.97.
View the best growth stocks for 2024 here

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its earnings results on Monday, May, 20th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.31 by $0.12. The company had revenue of $164.94 million for the quarter, compared to analyst estimates of $156.10 million. Taro Pharmaceutical Industries had a net margin of 8.56% and a trailing twelve-month return on equity of 3.75%.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS) and GW Pharmaceuticals (GWPH).

This page (NYSE:TARO) was last updated on 7/17/2024 by Staff

From Our Partners